Hematopoiesis News Volume 12.23 | Jun 15, 2021

    0
    108







    2021-06-15 | HN 12.23


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.23 – 15 June, 2021
    TOP STORY

    Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage Ambiguous Stem Cell Leukemia

    The authors described a distinct subgroup of acute leukemia with expression of myeloid, T lymphoid, and stem cell markers driven by aberrant allele-specific deregulation of BCL11B, a master transcription factor responsible for thymic T-lineage commitment and specification.
    [Cancer Discovery]

    Abstract
    Return to your lab safely and efficiently with these guides and resources so that you can focus more on moving your research goals forward.
    PUBLICATIONSRanked by the impact factor of the journal

    Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History

    Researchers employed mitochondrial single-cell assay for transposase-accessible chromatin with sequencing to profile 163,279 cells from nine patients with chronic lymphocytic leukemia collected across disease course and utilized mitochondrial DNA mutations as natural genetic markers of cancer clones.
    [Cancer Discovery]

    Abstract

    Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression

    Investigators discovered that internal tandem duplication within FLT3 (FLT3-ITD), one of the most frequent mutations in acute myeloid leukemia, was S-palmitoylated by the ZDHHC6 palmitoyl acyltransferase. Disruption of palmitoylation redirected FLT3-ITD to the plasma membrane and rewired its downstream signaling by activating AKT and ERK pathways in addition to STAT5.
    [Blood]

    Abstract

    Plasma from Patients with Bacterial Sepsis or Severe COVID-19 Induces Production of Suppressive Myeloid Cells from Human Hematopoietic Progenitor Cells In Vitro

    To examine the ontogeny and function of MS1 cells, scientists developed a cellular model for inducing CD14+ MS1 monocytes by treating human hematopoietic stem and progenitor cells from healthy bone marrow donors in culture with plasma from patients with severe bacterial infection or SARS-CoV-2 infection.
    [Science Translational Medicine]

    Full ArticlePress Release

    Targeted PI3K/AKT-Hyperactivation Induces Cell Death in Chronic Lymphocytic Leukemia

    Researchers hypothesized that targeted hyperactivation of the phosphatidylinositol-3-phosphate/AKT (PI3K/AKT)-signaling pathway may have been leveraged to trigger chronic lymphocytic leukemia cell death.
    [Nature Communications]

    Full Article

    Non-Conditioned Bone Marrow Chimeric Mouse Generation Using Culture-Based Enrichment of Hematopoietic Stem and Progenitor Cells

    The authors described their development of cell culture techniques for the enrichment of functional hematopoietic stem and progenitor cells from mouse bone marrow without the use of fluorescence-activated cell sorting purification.
    [Nature Communications]

    Full ArticlePress Release

    Fanconi Anemia Proteins Participate in a Break-Induced-Replication-Like Pathway to Counter Replication Stress

    Scientists showed that Fanconi anemia (FA)-mutated cells were hypersensitive to persistent replication stress and that FA proteins played a role in the break-induced-replication-like pathway for fork restart.
    [Nature Structural & Molecular Biology]

    Abstract

    Metabolic Alterations Mediated by STAT3 Promotes Drug Persistence in CML

    By exploring the role of STAT3 in altering metabolism, researchers provided insight into identifying potential therapeutic targets for eliminating tyrosine kinase inhibitor-persistent leukemic stem cells.
    [Leukemia]

    Full Article

    The Combination of Cudc-907 and Gilteritinib Shows Promising In Vitro and In Vivo Antileukemic Activity against FLT3-Itd AML

    Investigators showed that gilteritinib and CUDC-907, a dual inhibitor of PI3K and histone deacetylases, synergistically induced apoptosis in FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) cell lines and primary patient samples and had striking in vivo efficacy.
    [Blood Cancer Journal]

    Full Article

    Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50–75 Years of Age with Advanced Myelodysplastic Syndrome

    Scientists conducted a multicenter biologic assignment trial comparing reduced-intensity hematopoietic cell transplantation to hypomethylating therapy or best supportive care in subjects 50-75 years of age with intermediate-2 or high-risk de novo myelodysplastic syndromes.
    [Journal of Clinical Oncology]

    Full Article

    PRC2 Loss of Function Confers a Targetable Vulnerability to BET Proteins in T-ALL

    The authors analyzed Polycomb Repressor Complex 2 (PRC2) alterations in a large series of 218 adult T-cell acute lymphoblastic leukemia (T-ALL) patients and found that PRC2 genetic lesions were frequent events in T-ALL and were not restricted to ETP-ALL.
    [Blood]

    Abstract

    Association of Diet Quality with Prevalence of Clonal Hematopoiesis and Adverse Cardiovascular Events

    Researchers conducted a cohort study to examine whether there was an association between diet quality and the prevalence of clonal hematopoiesis of indeterminate potential.
    [JAMA Cardiology]

    Abstract

    Cryopreservation of Unrelated Donor Hematopoietic Stem Cells: The Right Answer for Transplantations during the COVID-19 Pandemic?

    Investigators compared 32 patients who underwent unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) using cryopreserved peripheral blood stem cells (PBSC) during the COVID-19 pandemic with 32 patients who underwent UD HSCT using fresh PBSC in the previous period.
    [Bone Marrow Transplantation]

    Full Article

    Image of erythroblasts which were simply & efficiently generated from PSCs using the STEMdiff Erythroid Kit.
    REVIEWS

    60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy

    The authors review the historical basis underpinning the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as advances in knowledge obtained by defining mechanisms of allo-HSCT activity.
    [Cancer Research]

    Abstract

    Inhibition of Translation Initiation Factor eIF4a Inactivates Heat Shock Factor 1 (HSF1) and Exerts Anti-Leukemia Activity in AML

    Investigators provide a novel therapeutic rationale for co-targeting eukaryotic initiation factor 4A (eIF4A) and FLT3 to address the clinical challenge of treating FLT3-mutant acute myeloid leukemia.
    [Leukemia]

    Abstract

    The Stem Cell Revolution: On the Role of CD164 as a Human Stem Cell Marker

    Scientists highlight research describing the extant human CD164 monoclonal antibody characteristics, which are critical for identifying and purifying both human hematopoietic and skeletal stem cells.
    [NPJ Regenerative Medicine]

    Full Article

    INDUSTRY AND POLICY NEWS

    Bristol
    Myers Squibb Announces Positive Topline Results from Phase III TRANSFORM Trial Evaluating Breyanzi (Lisocabtagene Maraleucel) versus Chemotherapy Followed by Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma

    Bristol Myers Squibb announced positive results from TRANSFORM, a Phase III study evaluating Breyanzi as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma compared to salvage therapy followed by high-dose chemotherapy and hematopoietic stem cell transplant.
    [Bristol Myers Squibb]

    Press Release

    GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease

    Global Blood Therapeutics, Inc. has awarded approximately $450,000 to US community-based organizations and institutions as part of the company’s 2021 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program. The program provides support to accelerate the development of sustainable access-to-care programs for people living with sickle cell disease.
    [Global Blood Therapeutic, Inc.]

    Press Release

    FEATURED EVENT

    EMBO Workshop: Cell Size and Growth Regulation

    June 21 – 24, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Associate Professor – Blood Cancer

    University of Wisconsin Madison – Madison, Wisconsin, United States

    Senior Scientist – Hematopoiesis and Blood Diseases

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Postdoctoral Positions – Hematopoiesis and Leukemia

    UT Southwestern Medical Center – Dallas, Texas, United Statess

    Faculty Positions – Immuno-Oncology

    Medical College of Wisconsin – Milwaukee, Wisconsin, United States

    Laboratory Technologist – Histocompatibility

    Memorial Sloan Kettering Cancer Center – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter